

Anti- α 4 β 7 Integrin (Vedolizumab), Humanized Antibody

rev 03/21

CATALOG NO.: A2140-100 (100 μ g)

BACKGROUND DESCRIPTION: Vedolizumab is a recombinant humanized IgG1 monoclonal antibody that selectively targets α 4 β 7 integrin expressed on the surface of T and B cell lymphocytes and prevents the association of the integrin with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This inhibits the inflammatory activity of the lymphocytic cells and its migration into the gut lamina propria and gut-associated lymphoid tissue (GALT). Vedolizumab was developed by Millennium Pharmaceuticals and received FDA approval in 2014 for the treatment of ulcerative colitis and Crohn's disease. Vedolizumab is marketed under the trade name of Entyvio®.

ALTERNATE NAMES: LDP 02, LDP-02, LDP02, MLN-0002, MLN-02, MLN0002, MLN02, ENTYVIO, α 4 β 7, ITGA4/ITGB7

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant/ IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Vedolizumab

MOLECULAR WEIGHT: 146.8 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C

APPLICATIONS AND USAGE: In vitro studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-TNF- α (Adalimumab), humanized Antibody (A1048)
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)
 Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)
 Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody (A1092)
 Anti-Integrin alpha 4 (Natalizumab), Human IgG4 Antibody (A1444)

FOR RESEARCH USE ONLY! Not to be used on humans.